A well-executed manufacturer corporate representative strategy can produce some of the most decisive evidence in an entire product liability case, often more powerful than any retained expert's opinion. This page outlines the deposition and discovery approach the firm applies against large corporate manufacturers, drawing on the framework behind the firm's trucking product defect trial, where the manufacturer's own alternative product design became central evidence.
2025.230
Code of Civil Procedure section authorizing the organizational deposition
1
Company witness whose testimony binds the entire organization
Under California Code of Civil Procedure section 2025.230, a party can notice a deposition directed at an organization itself, requiring the organization to designate one or more representatives to testify on its behalf regarding specifically identified topics. This tool, often called a person most knowledgeable or person most qualified deposition, lets plaintiff's counsel obtain sworn, binding testimony on behalf of the entire corporation regarding exactly the topics most central to the defect theory, rather than relying solely on individual employee depositions limited to personal knowledge.
The effectiveness of a manufacturer corporate representative strategy depends heavily on how precisely the deposition notice topics are drafted. Broad, vague topics invite broad, evasive answers and objections. Sharply defined topics, such as the specific design history of a particular component, the identity and substance of any internal risk assessments performed on that component, or the company's knowledge of alternative designs used in other product lines, force the company to prepare a witness who can speak to exactly the evidence plaintiff's counsel needs.
When a manufacturer produces multiple product lines or sells comparable products in different markets, the deposition should systematically explore what the company knew about safer designs used elsewhere in its own corporate family. Questions about why a safer design was not adopted in another line can reveal internal cost, timing, or profitability rationales that become central trial evidence.
Corporate representatives are frequently prepared to give narrow, technically accurate but substantively evasive answers. Effective questioning requires patience, precise follow-up that closes off evasion, and a willingness to return to the same topic from multiple angles. Documenting each non-answer on the record is itself valuable, since a pattern of evasiveness can be argued at trial or on motion.
The strategy works best after key documents arrive through written discovery. Confronting a witness with the company's own internal emails, engineering reports, or risk assessments during the deposition, and asking the witness to explain them in real time, often produces the most quotable and persuasive testimony in the entire case.
Testimony taken under this framework binds the organization and can be used at trial whether or not the individual witness later appears.
The case behind this page
The full trial story of a design defect proven with the company's own safer product line.
See how the manufacturer's own design became the caseRelated defense
Why federal compliance did not shield the manufacturer from a state law design defect claim.
The preemption analysisRelated breakdowns from this case on defeating the preemption defense and the design defect that drove the result.
We litigate product liability and trucking defect cases as counsel or co-counsel and pay statutory referral fees.
Refer a caseA corporate representative deposition, taken under California Code of Civil Procedure section 2025.230, requires an organization to designate a witness to testify on its behalf regarding specifically identified topics, producing sworn testimony binding on the entire company.
Precisely drafted topics force the company to prepare a witness who can speak directly to the specific evidence plaintiff's counsel needs, while broad or vague topics invite evasive answers and objections.
Questioning a corporate representative about safer designs used in the manufacturer's other product lines or markets can reveal internal cost or timing rationales for not adopting those designs elsewhere, which becomes powerful trial evidence.
